Supplements

Benralizumab reduces cough and/or dyspnea frequency and improves cough-specific health-related quality of life in patients with severe eosinophilic asthma in Asia

In a post-hoc analysis of the MIRACLE trial, benralizumab significantly increased the proportion of patients transitioning from frequent to non-frequent cough at Week 8 (54.0% vs 39.7%, p=0.0051) and improved cough-related SGRQ items earlier than placebo, with sustained benefits through Week 48. Similar improvements were seen for dyspnea frequency at Week 8 (64.2% vs 47.1%, p=0.0026) and Week 48 (75.5% vs 63.4%, p=0.0221). Benefits were more pronounced in patients with baseline blood eosinophil counts ≥300 cells/μL.

Last updated: Aug 30, 2026•1 RCTs•📖 Read as article →

Evidence Score

Evidence Score44/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Efficacy of benralizumab in reducing cough and/or dyspnea frequency, and improving cough-specific health-related quality of life in patients with severe eosinophilic asthma in Asia.

observational

Lai K, Sun D, Dai R, Xu X, Zhao J, Wu T, Ho CN, Werkström V, Cohen D, Necander S, Zhong N · Therapeutic advances in respiratory disease (2026)

Participants: N/A
Duration: 48 weeks
Intervention: Benralizumab (subcutaneous, standard dosing) compared to placebo
Outcome: Cough frequency, dyspnea frequency, cough-specific health-related quality of life (measured via SGRQ items)
Effect Size: N/A (only p-values and percentages reported)
Population: Patients aged 12-75 years with uncontrolled severe eosinophilic asthma in Asia, with baseline frequent cough (n=383) or frequent dyspnea (n=304)

Result:

PubMed: 42661269DOI: 10.1177/17534666261471304

Mechanism Graph

Benralizumab binds to IL-5 receptor alpha on eosinophils
↓
Induces rapid depletion of eosinophils via antibody-dependent cell-mediated cytotoxicity
↓
Reduces eosinophilic inflammation in airways
↓
Leads to reduced cough and dyspnea frequency and improved cough-specific HRQoL

Limitations

  • ⚠Post-hoc exploratory analysis, not pre-specified
  • ⚠Cough and dyspnea measured via SGRQ items, not validated cough-specific clinical endpoints
  • ⚠No long-term safety or efficacy data beyond 48 weeks
  • ⚠Subgroup analyses may be underpowered

Frequently Asked Questions

How quickly does benralizumab reduce cough in severe eosinophilic asthma?▼

Benralizumab showed significant improvement in cough frequency by Week 8, with 54.0% of patients transitioning to non-frequent cough compared to 39.7% with placebo.

Does benralizumab improve dyspnea in severe eosinophilic asthma?▼

Yes, benralizumab significantly reduced dyspnea frequency compared to placebo at both Week 8 (64.2% vs 47.1%) and Week 48 (75.5% vs 63.4%).

Are the benefits of benralizumab on cough and dyspnea sustained over time?▼

Yes, improvements in cough-related SGRQ items were sustained through Week 48, and dyspnea improvements were also maintained at Week 48.

Which patients benefit most from benralizumab for cough and dyspnea?▼

Patients with higher baseline blood eosinophil counts (≥300 cells/μL) showed more pronounced benefits, likely reflecting a higher inflammatory burden.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Lai K, Sun D, Dai R, Xu X, Zhao J, Wu T, Ho CN, Werkström V, Cohen D, Necander S, Zhong N. "Efficacy of benralizumab in reducing cough and/or dyspnea frequency, and improving cough-specific health-related quality of life in patients with severe eosinophilic asthma in Asia.." Therapeutic advances in respiratory disease, 2026. PMID: 42661269 DOI: 10.1177/17534666261471304
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.